InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,308.13
(
0.09%
)
US TECH 100
18,177.20
(
-0.11%
)
Dow Jones
39,806.77
(
-0.49%
)
Brent Oil
82.55
(
-1.17%
)
Bitcoin
71,244.77
(
-0.29%
)
Post# of 29334
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119663
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: wow_happens28 post# 8816

Tuesday, 09/16/2014 11:50:13 AM

Tuesday, September 16, 2014 11:50:13 AM

Post# of 29334
Inasmuch as many diabetes patients eventually end up on dialysis, an alternative way of playing the global epidemic in diabetes is by investing in companies who participate in the dialysis business. After the spinoff of its pharma business in 1H15, BAX will derive a large proportion of its sales from dialysis.

NVO (as jbog mentioned) has long been a leader in diabetes, but its valuation is rather rich.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up